A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

Neoplasms

Interventions

DRUG

NM-3

Trial Locations (1)

Boston

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00046696 - A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter